The global dengue vaccine market is anticipated to grow at a significant CAGR during the forecast period (2022-2028). Dengue fever is an infectious disease spread by mosquitos that affects both animals and humans. It is caused by the dengue virus, which belongs to the Flaviviridae family and genus Flavivirus. It spreads from one person to another through the bite of an infected Aedes Aegypti mosquito. Dengue fever is characterized by a high temperature, exhaustion, headache, diarrhea, muscle discomfort, skin rashes, anemia, and vomiting. Seizures, yellow skin, and unconsciousness are among symptoms of dengue fever in its most severe form. It has a high death rate and can lead to significant neurological problems. Dengue fever causes CNS symptoms such as aberrant neurological signals, altered consciousness, delirium, and generalized and localized convulsions.

The key companies operating in the industry are highly inclined towards the adoption of different growth strategies including partnerships and collaborations, mergers and acquisitions, geographical expansion, and new product launches, to remain competitive in the marketplace. For instance, Takeda Pharmaceutical Company Limited announced in March 2021 that the European Medicines Agency (EMA) had accepted the Company's filing packages for its dengue vaccine candidate (TAK-003), which is being investigated for the prevention of dengue due to any dengue virus serotype in people aged four to sixty. During the year 2021, Takeda filed regulatory documents in Argentina, Brazil, Colombia, Indonesia, Malaysia, Mexico, Singapore, Sri Lanka, and Thailand. The tetravalent dengue vaccine candidate (TAK-003) developed by Takeda is based on a live-attenuated dengue serotype 2 virus, which serves as the genetic "backbone" for all four vaccine viruses. TAK-003 produced immunological responses against all four dengue serotypes in both seropositive and seronegative subjects, which lasted for 48 months following vaccination, according to clinical Phase 2 results in children and adolescents. The vaccine was also shown to be generally safe and well tolerated.

Market Coverage

• The market number available for – 2021-2027
• Base year- 2021
• Forecast period- 2022-2028

Segment Covered- 

• By Product 
• By End-User 

Regions Covered-

• North America
• Europe
• Asia-Pacific
• Rest of the World

Competitive Landscape- Sanofi S.A., Takeda Pharmaceutical Company Limited, Sun Pharmaceutical Industries Ltd, and Merck & Co. Inc., among others. 

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How has COVID-19 impacted the market?

o Deviation from the pre-COVID-19 forecast

o Most affected region and segment

• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Dengue Vaccine Market Report by Segment

By Drug Type 

• CYD-TDV [Dengvaxia] 
• Others

By End-User 

• Government Institutes,
• Specialty Clinics
• Hospitals
• Others

Global Dengue Vaccine Market Report by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe 

Asia-Pacific 

• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific 

Rest of the World

• Latin America 
• Middle East & Africa